Heather E. Oakervee

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients.

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 05, 2021

Optimising cardiovascular care of patients with multiple myeloma.

Optimising cardiovascular care of patients with multiple myeloma.

Journal: Heart (British Cardiac Society)

Published: November 30, 2020

Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience.

Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience.

Journal: British journal of haematology

Published: November 08, 2020

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma.

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma.

Journal: Clinical hematology international

Published: October 22, 2020

Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence.

Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence.

Journal: Nature communications

Published: September 03, 2020

Clinical outcome of coronavirus disease 2019 in haemato-oncology patients.

Clinical outcome of coronavirus disease 2019 in haemato-oncology patients.

Journal: British journal of haematology

Published: May 19, 2020

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

Journal: Blood cancer journal

Published: April 09, 2020

Advanced Imaging Modalities to Monitor for Cardiotoxicity.

Advanced Imaging Modalities to Monitor for Cardiotoxicity.

Journal: Current treatment options in oncology

Published: August 10, 2019

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Journal: Annals of hematology

Published: January 09, 2019

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.

Journal: Toxicology reports

Published: December 14, 2018

Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.

Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.

Journal: British journal of haematology

Published: September 27, 2018

Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).

Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).

Journal: British journal of haematology

Published: August 21, 2018

Showing 1-12 of 24

Last Updated: 09/26/2026